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Background: Dose-dense sequential chemotherapy including anthracyclines and taxanes has been established in
the adjuvant setting of high-risk operable breast cancer. However, the preferable taxane and optimal schedule of
administration in a dose-dense regimen have not been defined yet.
Methods: From July 2005 to November 2008, 1001 patients (990 eligible) were randomized to receive, every
2 weeks, 3 cycles of epirubicin 110 mg/m2 followed by 3 cycles of paclitaxel 200 mg/m2 followed by 3 cycles of
intensified CMF (Arm A; 333 patients), or 3 cycles of epirubicin followed by 3 cycles of CMF, as in Arm A, followed
3 weeks later by 9 weekly cycles of docetaxel 35 mg/m2 (Arm B; 331), or 9 weekly cycles of paclitaxel 80 mg/m2
(Arm C; 326). Trastuzumab was administered for one year to HER2-positive patients post-radiation.
Results: At a median follow-up of 60.5 months, the 3-year disease-free survival (DFS) rate was 86%, 90% and 88%, for
Arms A, B and C, respectively, while the 3-year overall survival (OS) rate was 96% in all arms. No differences were found in
DFS or OS between the combined B and C Arms versus Arm A (DFS: HR = 0.81, 95% CI: 0.59-1.11, P = 0.20; OS: HR = 0.84,
95% CI: 0.55-1.30, P = 0.43). Among the 255 patients who received trastuzumab, 189 patients (74%) completed 1 year of
treatment uneventfully. In all arms, the most frequently reported severe adverse events were neutropenia (30% vs. 27% vs.
26%) and leucopenia (12% vs. 13% vs. 12%), while febrile neutropenia occurred in fifty-one patients (6% vs. 4% vs. 5%).
Patients in Arm A experienced more often severe pain (P = 0.002), neurological complications (P = 0.004) and allergic
reactions (P = 0.004), while patients in Arm B suffered more often from severe skin reactions (P = 0.020).
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Conclusions: No significant differences in survival between the regimens were found in the present phase III trial. Taxane
scheduling influenced the type of severe toxicities. HER2-positive patients demonstrated comparable 3-year DFS and OS
rates with those reported in other similar studies.
Trial registration: Australian New Zealand Clinical Trials Registry ACTRN12610000151033.
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Breast cancer represents the most common cancer in
women in western countries, while its incidence rate
constantly increases in developing countries [1]. Adju-
vant systemic therapy has significantly reduced the
death rate of this disease [2]. In the last two decades,
clinical research on adjuvant chemotherapy of early
breast cancer (EBC) has been characterized by the
conceptualization of new principles, such as dose-density
and sequential chemotherapy [3] and the incorporation of
taxanes to anthracycline-based chemotherapy.
The impact of dose-density (i.e., the increase of dose-
intensity [DI] by reducing the interval between cycles
with the use of granulocyte-colony stimulating factors
[G-CSF]) on the outcome of patients treated with adju-
vant chemotherapy has been extensively studied by
several cooperative groups. A recently published meta-
analysis showed that dose-dense adjuvant chemotherapy
significantly improves disease-free survival (DFS) of pa-
tients with EBC compared to conventional chemotherapy
without, however, demonstrating an apparent benefit in
overall survival (OS) [4]. Further, sequential adjuvant
chemotherapy significantly prolongs both DFS and OS
over concurrent chemotherapy in this group of patients,
as also shown in a meta-analysis including three trials
with a total of over 8500 patients [5].
The impact of the incorporation of taxanes to adjuvant
chemotherapy on the outcome of patients with EBC has
been evaluated in numerous randomized trials. In an
overview published recently by the Early Breast Cancer
Trialists’ Cooperative Group [6], it was clearly shown
that the addition of a taxane to anthracycline-based regi-
mens, slightly, but significantly improved outcome.
Nevertheless, despite the proven beneficial effect of
taxanes, the optimal taxane and the optimal schedule of
administration remained for over a decade under inten-
sive investigation. The weekly administration of doce-
taxel or paclitaxel has been studied in numerous clinical
studies (reviewed in reference [7]) in patients with meta-
static breast cancer. Further, several investigators incorpo-
rated docetaxel or paclitaxel weekly schedules to adjuvant
chemotherapy regimens in large randomized trials in pa-
tients with EBC [8-12].
In 2005 and early 2006, the results of four randomized
trials investigating the role of trastuzumab when addedto adjuvant chemotherapy in patients with HER2-
positive EBC were published [13-15]. These seminal tri-
als demonstrated a remarkable reduction in relapse and
death rates from the addition of trastuzumab [16,17].
The beneficial effect of trastuzumab was shown in two
additional trials published a few years later, one in the
adjuvant [18] and one in the neo-adjuvant setting [19].
The Hellenic Cooperative Oncology Group (HeCOG)
has been involved in this field of clinical research by con-
ducting two randomized trials exploring, in the first, the
role of paclitaxel (Taxol®, Bristol Myers Squibb, Princeton,
NJ) in a dose-dense sequential regimen with epirubicin
and CMF [20] and in the second, the efficacy of a dose-
dense sequential regimen with epirubicin, paclitaxel and
CMF compared to that of concurrent administration of
epirubicin and paclitaxel followed by CMF [21,22].
Following the completion of these studies, two feasibility
studies were performed in the adjuvant setting, one with
weekly docetaxel [23] and the other with weekly paclitaxel
[24], sequentially administered after 3 cycles of epirubicin
and 3 cycles of CMF given in a dose-dense fashion. Since
the tolerability and safety of these regimens were satisfac-
tory, we designed and conducted a 3-arm randomized trial
(HE10/05) comparing the above-mentioned regimens with
that of dose-dense epirubicin, paclitaxel and CMF (E-T-
CMF). The latter was extensively studied in the two previ-
ously cited randomized trials [20-22] and served in the
present trial as the control arm.
The primary endpoint of the trial was 3-year DFS. Sec-
ondary endpoints were 3-year OS and acute toxicity.
Notably, the current trial incorporated a collateral trans-
lational research part, which included the prospective
collection of biological material for the investigation of
the predictive/prognostic significance of key biological
markers and pathways. We report here the results of the




Eligible women were older than 18 years with histologi-
cally confirmed node-positive (T1-3 N1M0) or “intermedi-
ate risk” according to the 2005 St. Gallen criteria [25]
(node negative patients with at least one of the following
features: pT > 2 cm, or histological and/or nuclear grade
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HER2 gene overexpression and/or amplification, or age
<35 years) adenocarcinoma of the breast. Patients had to
have breast-conserving surgery with tumor-free margins
or modified radical mastectomy, adequate hematologic,
hepatic and renal function, performance status of 0 to 1 of
the Eastern Cooperative Oncology Group (ECOG) scale,
without evidence of significant cardiac disease (a normal
left ventricular ejection fraction [LVEF] demonstrated by a
Multiple Gated Acquisition [MUGA] scan or echocardio-
gram). Reasons for non-eligibility are described in detail
[see Additional file 1].
Before randomization, each patient provided study
specific written informed consent for participating in the
trial and optionally a separate informed consent for pro-
viding biological material for research purposes. All clin-
ical investigations related to the present study have been
conducted according to the principles expressed in the
Declaration of Helsinki.
The clinical protocol was approved by the Institutional
Review Boards in participating centers (“Agii Anargiri”
Cancer Hospital, “Alexandra” Hospital, “Attikon” Univer-
sity Hospital, “Errikos Dynan” Hospital, “Hygeia” Hospital,
“Papageorgiou” Hospital, University Hospital of Ioannina,
University Hospital of Larissa, University Hospital of Pa-
tras) and by the National Organization for Medicines. The
trial was included in the Australian New Zealand Clinical
Trials Registry (ANZCTR) and allocated the following
Registration Number: ACTRN12610000151033.
Pretreatment evaluation included medical history, clin-
ical examination, chest X-rays and abdominal ultra-
sonography (or computed tomography [CT] scans in
patients with more than nine infiltrated axillary nodes or
if clinically indicated), bone scans, ejection fraction (EF),
complete blood count (CBC) and a comprehensive bio-
chemistry panel. CBC and biochemistries were repeated
before each cycle and EF after the completion of chemo-
therapy and then every 4 months during treatment with
trastuzumab. Furthermore, CBC was done between cy-
cles in the case of fever over 38oC, severe stomatitis or
diarrhea.
Treatment
Stratified block randomization (1:1:1), balanced by cen-
ter, was performed centrally at the HeCOG Data Office
in Athens by telephone. Stratification factors included
menopausal status (pre vs. post), hormonal receptor sta-
tus (positive vs. negative) and number of involved axil-
lary lymph nodes (0 vs. 1-3 vs. ≥4). Patients were
randomized to receive one of the following three chemo-
therapeutic schedules: three cycles of epirubicin (E,
110 mg/m2) every 2 weeks followed by 3 cycles of pacli-
taxel (T, 200 mg/m2) every 2 weeks followed by 3 cycles
of intensified CMF (cyclophosphamide 840 mg/m2,methotrexate 57 mg/m2 and fluorouracil 840 mg/m2)
every 2 weeks (Arm A, E-T-CMF), or three cycles of
epirubicin followed by 3 cycles of CMF, as in Arm A,
followed 3 weeks later by 9 consecutive weekly cycles of
docetaxel (wD) 35 mg/m2 (Arm B, E-CMF-wD), or 9
consecutive weekly cycles of paclitaxel (wT) 80 mg/m2
(Arm C, E-CMF-wT).
G-CSF was given following each cycle in Arm A and
during the intensified phase of epirubicin and CMF
treatments in Arms B and C. Dose modifications are
shown in detail [see Additional file 1]. The National
Cancer Institute Common Terminology Criteria for Ad-
verse Events, Version 3.0 were used to assess toxicity.
Patients with HER2-positive tumors were treated with
trastuzumab, initially at a dose of 8 mg/kg as a loading
dose, and subsequently 6 mg/kg every three weeks for
one year. Initially, HER2-positive tumors were consid-
ered those with an immunohistochemistry (IHC) score
of 3+ (uniform, intense membrane staining of >10% of
invasive tumor cells), a fluorescence in situ hybridization
(FISH) result of ≥6 HER2 gene copies, or a FISH ratio
(HER2 gene signals to chromosome 17 signals) of >2.0.
Following the 2007 publication of the American Society
of Clinical Oncology/College of American Pathologists
guideline recommendations for HER2 testing in breast
cancer [26], the criteria for characterizing a tumor as
HER2-positive were updated (the FISH ratio was chan-
ged to >2.2).
Ondansetron ± dexamethasone were recommended as
antiemetic treatment in all patients. Radiation therapy
(RT) was required for all patients who underwent partial
mastectomy or those with tumor size ≥5 cm and/or
more than 4 positive lymph nodes, irrespective of the
type of surgery (conservative or radical). Details for
the RT technique are given [see Additional file 1]. RT
was initiated 3-4 weeks following the completion of
chemotherapy.
Premenopausal patients with hormone receptor-
positive status received oral tamoxifen 20 mg daily for
5 years and goserelin 10.8 mg subcutaneously every
3 months for 2 years. Postmenopausal patients with hor-
mone receptor-positive status were treated daily with
anastrazole 1 mg orally for 5 years. Postmenopausal pa-
tients were considered those without menses for the last
two years or those older than 50 years who underwent a
hysterectomy for non-malignant reasons. Tumors were
considered hormone receptor-positive if ≥1% of tumor
cell nuclei were stained. It has to be noted that in the
present analysis, hormone receptor status and HER2 sta-
tus are presented as assessed by local laboratories. Tras-
tuzumab and hormonal therapies were administered
following the completion of chemotherapy and RT.
Data entry was performed in a central database by
trained HeCOG data managers located at the different
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tored by certified HeCOG personnel.
Follow-up
All patients were followed at the Clinic, at study entry,
every six months for the first five years and annually
thereafter with clinical examinations, CBC, biochemistry
panels, serological markers, chest X-rays and abdominal
ultrasonography (or CT scans if clinically indicated).
Mammography and ultrasonography of the breasts were
performed annually. Bone scans were not routinely done
after the third year, except when clinically indicated.
Statistical analysis
In this multicenter phase III randomized, open-label,
comparative trial (parallel assignment and efficacy study)
the primary objective on an intent-to-treat analysis was
DFS. Based on the initial hypothesis that the epirubicin,
CMF and weekly docetaxel or weekly paclitaxel arms
(Arms B and C) were equally effective on DFS, a com-
parison of the combined Arms B and C to the epirubi-
cin, paclitaxel and CMF arm (Arm A), was of interest.
One thousand patients were required to be randomized
to the study to detect a 5% difference between the com-
bined arms (Arms B and C) vs. the control arm (Arm
A), with a two-sided test at the 5% level of significance
and a power of 80%, assuming a 3-year DFS rate of 80%
for the control arm. The study accrual rate was esti-
mated at 330 patients per year and the maximum study
duration was estimated to be 8.1 years for observing a
total of 329 relapses. An interim analysis based on the
O’Brien Fleming boundary values was to be performed
when 50% of the events had been reached.
DFS was defined based on the interval from study
entry to first locoregional recurrence, first distant metas-
tasis, contralateral breast cancer, secondary neoplasm,
death from the disease or death from any cause, which-
ever occurred first. OS was measured from study entry
until death from any cause. Surviving patients were cen-
sored at the date of last contact.
Fisher’s exact or Pearson chi-square tests were used
for group comparisons of categorical data, while for con-
tinuous data the non-parametric Mann-Whitney or the
Kruskall-Wallis tests were used, where appropriate. Sur-
vival distributions were estimated using the Kaplan-
Meier method. The significance nominal level for the
tests of the hypotheses was set at p < 0.05.
For the univariate and multivariate analyses, Cox pro-
portional hazards models were used. In the multivariate
setting, model choice was performed using backward se-
lection criteria with P < 0.10, including in the initial step
clinicopathological parameters, menopausal status (post
vs. premenopausal), number of positive nodes (≥4 and 1-
3 vs. 0), tumor size (>2 vs. ≤2), histological grade (3 vs.1 + 2), ER/PgR status (positive vs. negative) and HER2 sta-
tus (positive vs. negative), in the presence of randomization
arm (combined Arms B and C vs. Arm A). The final multi-
variate models are presented by forest plots.
All endpoints except adverse events and treatment
characteristics were analyzed according to the intent-to-
treat (ITT) principle. The reported P-values are two-
sided. Survival status was updated in July 2012. The
SPSS (version 15.0, IBM Corporation, Armonk, NY) and
SAS (version 9.3, SAS Institute Inc., Cary, NC) software
were used for statistical analysis.
Results
Patient population
From July 2005 until November 2008, 1001 patients
were randomized (990 eligible; 333, 331 and 326 in
Arms A, B and C, respectively). Eleven patients were
deemed non- eligible (4 patients with M1 disease, one
with bilateral breast cancer, one with co-existing renal
cancer, one with inadequate examination of lymph nodes
and 4 with violations in the randomization procedure).
Furthermore, 4 patients withdrew consent prior to re-
ceiving protocol treatment.
The progress of patients through the various stages of
the trial according to the Consolidation Standards of
Reporting Trials (CONSORT) flow diagram is shown in
Figure 1. Selected patient and tumor characteristics are
presented in Table 1. All characteristics were well bal-
anced between the treatment arms (Pearson chi-square
test, all P-values above 0.05).
Treatment compliance
Totally, 885 (89.4%) patients (306 in Arm A, 279 in Arm
B and 300 in Arm C) completed chemotherapy. Dose in-
tensities (DI) of all drugs are given in Table 2. The dis-
continuation rate was significantly lower in the E-T-
CMF arm [6.7% in Arm A vs. 12.5% in Arms B and C
(12.3% and 12.8%, respectively), P = 0.004]. Treatment
compliance and reasons for early chemotherapy discon-
tinuation are summarized [see Additional file 2: Table
S1]. The main reasons for discontinuation, observed in
105 patients (10.6% of the total study population), were
toxicity in 38 of the 105 patients (36%) and voluntary
withdrawal in 38 patients (36%).
Among 274 patients with HER2-positive tumors, tras-
tuzumab was administered in 254 patients (90, 84 and
80 in Arms A, B and C, respectively). Twenty patients
(7.3%) did not receive trastuzumab, despite being found
with HER2-positive tumors (12 patients because of vol-
untary withdrawal, 2 never starters and 6 with early re-
lapse). One HER2-negative patient (IHC score 2+),
randomized to Arm C, was treated with trastuzumab for
three months, until the FISH result was reported to be
negative. Compliance of patients to treatment with
Figure 1 CONSORT diagram.
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received trastuzumab, 189 patients (74%) (69, 58 and 62)
completed 1 year of treatment uneventfully. Reasons for
trastuzumab discontinuation are shown in the footnote
of Table 3. Finally, there were 13 patients [7 in Arm A
vs. 6 in Arms B and C, P = 0.23] who were treated with
trastuzumab for more than 1 year, based on patient
preference.
Efficacy
After a median follow-up time of 60.5 months (range,
0.1-79.0), 160 disease-defining events (61 vs. 50 and 49)
were recorded. At the time of this analysis (July 2012), 129
(13%) of the patients (51 vs. 40 and 38) had demonstrated
disease progression and 88 (8.9%) (33 vs. 25 and 30) had
died. Sites of relapse according to randomization arm are
presented in detail [see Additional file 2: Table S2]. Seven
patients (0.7%) developed second neoplasm (colorectal
cancer in 2, contralateral breast cancer in 2, lung cancer,ovarian cancer and peritoneal carcinomatosis in one pa-
tient each). One additional patient in Arm B was diag-
nosed, 3 years after the completion of chemotherapy, with
secondary acute myelogenous leukemia. The majority of
the patients (69%) died from tumor disease, while seven
patients (0.7%) died during adjuvant chemotherapy from
causes displayed in Table 4. Three-year DFS rates were
86.1%, 90.3% and 88.3% in arms A, B and C, respectively,
while 3-year OS rates were 95.8%, 96.3% and 95.7%. No
significant differences were observed in DFS and OS be-
tween the combined B and C Arms versus Arm A (DFS:
Hazard ratio [HR] = 0.81, 95% Confidence Interval [CI]:
0.59-1.11, Wald’s P = 0.20; OS: HR = 0.84, 95% CI: 0.55-
1.30, Wald’s P = 0.43) (Figure 2). Moreover, Arms B and C
were equally effective on DFS and OS, as initially assumed
[see Additional file 2: Figure S1].
The present interim analysis was conducted at ap-
proximately half of the events. Follow-up is ongoing
until the required events for the primary endpoint are










Median (range) 53 (28-79) 53 (21-78) 54 (23-78) 53 (21-79)
N (%) N (%) N (%) N (%)
Menopausal status
Premenopausal 155 (46.5) 157 (47.4) 149 (45.7) 461 (46.6)
Postmenopausal 178 (53.5) 174 (52.6) 177 (54.3) 529 (53.4)
Surgery
MRM 167 (50.2) 163 (49.2) 175 (53.7) 505 (51.0)
Partial mastectomy 166 (49.8) 168 (50.8) 151 (46.3) 485 (49.0)
Tumor size
≤2 159 (47.7) 139 (42.0) 119 (36.5) 417 (42.1)
2.1-5 155 (46.5) 169 (51.1) 183 (56.1) 507 (51.2)
>5 19 (5.7) 23 (6.9) 24 (7.4) 66 (6.7)
Positive nodes
0 83 (24.9) 80 (24.2) 83 (25.5) 246 (24.8)
1-3 136 (40.8) 136 (41.1) 136 (41.7) 408 (41.2)
≥4 114 (34.2) 115 (34.7) 107 (32.8) 336 (33.9)
Histological grade
1 25 (7.5) 16 (4.8) 20 (6.1) 61 (6.2)
2 155 (46.5) 141 (42.6) 152 (46.6) 448 (45.3)
3 153 (45.9) 174 (52.6) 154 (47.2) 481 (48.6)
Histological type
Invasive ductal NOS 274 (82.3) 273 (82.5) 279 (85.6) 826 (83.4)
Invasive lobular 31 (9.3) 28 (8.5) 22 (6.7) 81 (8.2)
Mixed type 18 (5.4) 18 (5.4) 11 (3.4) 47 (4.7)
Medullary 6 (1.8) 6 (1.8) 4 (1.2) 16 (1.6)
Mucinous 2 (0.6) 1 (0.3) 2 (0.6) 5 (0.5)
Papillary 1 (0.3) 3 (0.9) 3 (0.9) 7 (0.7)
Tubular - - 1 (0.3) 1 (0.1)
Apocrine - 1 (0.3) 1 (0.3) 2 (0.2)
Metaplastic - 1 (0.3) - 1 (0.1)
Neuroendocrine - - 1 (0.3) 1 (0.1)
Myeloepithelioma - - 1 (0.3) 1 (0.1)
Other 1 (0.3) - 1 (0.3) 2 (0.2)
Hormone receptor status
Negative 74 (22.2) 74 (22.4) 71 (21.8) 219 (22.1)
Positive 259 (77.8) 257 (77.6) 255 (78.2) 771 (77.9)
HER2 overexpression
No 239 (71.8) 240 (72.5) 237 (72.7) 716 (72.3)
Yes 94 (28.2) 91 (27.5) 89 (27.3) 274 (27.7)
Triple-negative
No 292 (87.7) 288 (87.0) 291 (89.3) 871 (88.0)
Yes 41 (12.3) 43 (13.0) 35 (10.7) 119 (12.0)
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Table 1 Patient and tumor characteristics per study arm1 and in the total study population (Continued)
Post-chemotherapy treatment
Adjuvant hormonal therapy
No 83 (24.9) 85 (25.7) 83 (25.5) 251 (25.4)
Yes 250 (74.1) 246 (74.3) 243 (74.5) 739 (74.6)
Tamoxifen 122 (36.6) 113 (34.1) 105 (32.2) 340 (34.3)
LH-RH 101 (30.3) 94 (28.4) 97 (29.8) 292 (29.5)
Aromatase inhibitor 150 (45.0) 152 (45.9) 163 (50.0) 465 (47.0)
Fulvestrant 1 (0.3) 1 (0.3) 1 (0.3) 3 (0.3)
Adjuvant radiotherapy
No 89 (26.7) 95 (28.7) 89 (27.3) 273 (27.6)
Yes 244 (73.3) 236 (71.3) 237 (72.7) 717 (72.4)
Trastuzumab treatment
No 243 (73.0) 247 (74.6) 245 (75.2) 735 (74.2)
Yes 90 (27.0) 84 (25.4) 81 (24.8) 255 (25.8)
1No significant differences between treatment arms were found (Pearson chi-square test).
N number of patients, MRM modified radical mastectomy, NOS not otherwise specified.
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mately half of what was expected and thus, it will take
much longer than the anticipated study duration to ob-
serve the 329 DFS events.
Multivariate Cox regression analysis results for DFS and
OS are shown in Figure 3. Tumor grade, tumor size and
number of positive lymph nodes were identified as inde-
pendent prognostic factors for both DFS and OS.
In an exploratory analysis only among patients receiv-
ing trastuzumab, those treated with weekly taxanes had
significantly longer DFS (P = 0.024, log-rank) than those
in the control arm; OS however was similar (P = 0.26)
(Figure 4).
Toxicity
The incidence of severe adverse events is shown in
Table 5. The most common were neutropenia (28.0%),
leukopenia (12.4%), febrile neutropenia (5.3%), metabolic
disturbances (4.3%), mucositis (3.5%) and infection
(3.1%). Patients in Arm A more often experienced severe
arthralgias/myalias (P = 0.002), neurological complica-
tions (p = 0.004) and allergic reactions (P = 0.004), while
patients in Arm B more often suffered from severe skin
reactions (P = 0.020). Febrile neutropenia occurred in 51
patients despite the use of prophylactic G-CSF and was
fatal in two patients, one in Arm A and one in Arm B.
Adverse events of any grade, per treatment arm, are
shown in detail [see Additional file 2: Table S3].
Discussion
A few years ago, a real breakthrough occurred in the
management of patients with EBC and HER2-positive
disease, with the publication of four randomized trials
investigating the addition of trastuzumab to adjuvantchemotherapy [13-15]. The primary endpoint in all trials
was DFS. Trastuzumab was administered concurrently
or sequentially to a variety of chemotherapeutic regi-
mens for at least 1 year. The only trial testing a shorter
duration was the Finnish trial [15], in which trastuzumab
was given for 9 weeks. The HERA trial [14] randomized
patients to receive trastuzumab for 1 or 2 years. In the
following years, the results of two additional trials
[18,27] and of further analyses with longer follow-up of
the four initial trials were also published [28-31]. In all
studies, except one [27], DFS (and OS in some) was sig-
nificantly improved with the addition of trastuzumab
[16,17]. It is notable that, in the final analysis of the Fin-
HER trial [31] with a median follow up of 5 years, even
though the beneficial effect of trastuzumab on DFS was
not present, a preplanned exploratory analysis within the
HER2-positive group revealed that the subset of patients
treated with docetaxel, trastuzumab and FEC had a su-
perior DFS to that of patients who received docetaxel
and FEC (HR= 0.32; P = 0.023) and to that of patients
treated with vinorelbine, FEC and trastuzumab (HR = 0.31;
P = 0.020). No significant difference was observed in OS.
In the present study, we hypothesized that modifying
the schedule of administration of taxanes i.e., docetaxel
or paclitaxel to weekly instead of 2-weekly in an adju-
vant dose-dense regimen, might improve DFS in patients
with intermediate or high-risk operable breast cancer. In
the current analysis, a significant difference in DFS be-
tween the treatment regimens has not been detected.
The conditional power at half of the information time is
44% and the study continues to completion.
The optimal schedule of both taxanes following
anthracycline-based chemotherapy was investigated in an
Intergroup trial lead by Eastern Cooperative Oncology







N (%) N (%) N (%)
Number of cycles per patient
1 1 (0.3) 2 (0.6) 3 (0.9)
2 2 (0.6) 2 (0.6) 3 (0.9)
3 1 (0.3) 2 (0.6) -
4 3 (0.9) 2 (0.6) 3 (0.9)
5 4 (1.2) - -
6 3 (0.9) 2 (0.6) 6 (1.8)
7 1 (0.3) 1 (0.3) 1 (0.3)
8 6 (1.8) 2 (0.6) 2 (0.6)
9 306 (93.6) 2 (0.6) 4 (1.2)
10 - 2 (0.6) -
11 - 1 (0.3) -
12 - 3 (0.9) 2 (0.6)
13 - 4 (1.3) 7 (2.0)
14 - 12 (3.8) 10 (2.9)
15 - 280 (88.3) 301 (88.0)
Total cycles given 2867 4560 4886
Median (range) 9 (1-9) 15 (1-15) 15 (1-15)
Median (range) Median (range) Median (range)
Dose intensity (DI)
Epirubicin 54 (26-58) 54 (26-64) 54 (30-64)
Paclitaxel 100 (57-105) - 78 (20-121)
Cyclophosphamie 410 (204-650) 414 (191.5-490) 410 (170-486)
Methotrexate 28 (14-44) 28 (13.2-43) 28 (11-43)
Fluorouracil 410 (204-650) 414 (191.5-490) 410 (170-486)
Docetaxel - 34 (15.7-80) -
Relative dose intensity (RDI)
Epirubicin 1.0 (0.5-1.1) 1.0 (0.5-1.2) 1.0 (0.6-1.2)
Paclitaxel 1.0 (0.6-1.1) - 1.0 (0.3-1.5)
Cyclophsphamide 1.0 (0.5-1.6) 1.0 (0.5-1.2) 1.0 (0.4-1.2)
Methotrexate 1.0 (0.5-1.5) 1.0 (0.5-1.5) 1.0 (0.4-1.5)
Fluorouracil 1.0 (0.5-1.6) 1.0 (0.5-1.2) 1.0 (0.4-1.2)
Docetaxel - 1.0 (0.5-2.3) -
N number of patients.
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http://www.biomedcentral.com/1471-2407/14/515Group (ECOG) [11]. In that pivotal trial, 4950 women
with node-positive or high-risk node-negative breast can-
cer were randomized to receive postoperatively four cycles
of doxorubicin and cyclophosphamide (AC) every three
weeks followed by docetaxel or paclitaxel at 3-week inter-
vals for four cycles or at 1-week intervals for 12 cycles.
Weekly paclitaxel following anthracycline/cyclophospha-
mide chemotherapy appeared to be more effective than 3-
weekly paclitaxel (HR = 1.27, P = 0.006 and HR = 1.32, P =0.01 for DFS and OS, respectively). Conversely, 3-weekly
docetaxel was superior to 3-weekly paclitaxel in DFS
(HR = 1.23, P = 0.02), although not in OS (HR = 1.13, P =
0.25). At the time we designed the present study, the re-
sults of the ECOG E1199 trial [11] were not available, and
thus assuming similar efficacy, we used in the experimen-
tal arms the weekly schedules of both taxanes.
A notable difference among the two trials was that our
patients with HER2-positive tumors received trastuzumab














No 243 (73) 247 (75) 245 (75) 735 (74)
Yes 90 (27) 84 (25) 81 (25) 255 (26)
Completed 1 year uneventfully 69 (77) 58 (69) 62 (77) 189 (74)
Discontinued
Temporarily1 13 (14) 16 (19) 12 (15) 41 (16)
Permanently2 8 (9) 10 (12) 7 (9) 25 (10)
1Treatment delay (n = 5), asymptomatic reduction of ejection fraction (n = 1), infection (n = 3), voluntary withdrawal (n = 28), not defined (n = 4).
The temporary discontinuation of the trastuzumab treatment was short in duration, with a median discontinuation time of 3 weeks, with 39 of the 41 patients
(95%) eventually receiving a full year of trastuzumab treatment.
2Chronic heart failure (n = 3), asymptomatic reduction of ejection fraction (n = 4), disease progression (n = 7), withdrawal of consent (n = 9), other (n = 2).
N number of patients.
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http://www.biomedcentral.com/1471-2407/14/515for 1 year. Given the available information at the time of
our study design, we selected to offer trastuzumab for 1 year
sequentially to chemotherapy, since this strategy was in ac-
cordance to that adopted in two of the published adjuvant
trastuzumab studies [13,14]. Importantly, 3-year and 5-year
DFS rates observed in the present analysis were similar to
those reported in the pivotal adjuvant trastuzumab trials.
Nevertheless, despite the wealth of clinical data avail-
able on the adjuvant treatment with trastuzumab, critical
issues, such as optimal duration (1 year or shorter dur-
ation), sequence (concurrently or sequentially to chemo-
therapy), optimal chemotherapeutic regimen or schedule
of administration of trastuzumab, are still a matter of
controversy. Regarding the issue of optimal duration of
treatment with trastuzumab, information on head to
head comparisons between 1 year and shorter duration
(6 months) [32] or longer duration (2 years) [33] have
recently been reported, suggesting that at present 1 year
of adjuvant trastuzumab should remain the standard
treatment. Results from the Finish Synergism or Long
Duration (SOLD; NCT00593697) study, exploring the
tantalizing issue of testing 9 weeks versus 1 year of tras-
tuzumab, which is tightly associated with patients’ con-
venience and reduced toxicity and treatment costs, are
still pending.Table 4 Cause of death during chemotherapy
Cause of death N Treatme
Febrile neutropenia 1 B
Febrile neutropenia 1 A
Infection (Hepatitis B reactivation) 1 A
Pulmonary embolism 1 C
Acute myocardial infarction 1 C
Acute respiratory failure 1 B
Unspecified 1 C
N number of patients, CT chemotherapy.As far as the issue of sequence is concerned, data from
the recent analysis of the N9831 trial [34] and a meta-
analysis [35] strongly support the superiority of concur-
rent over the sequential use of trastuzumab.
It is generally accepted that the type of chemotherapy
given concurrently with trastuzumab does not affect effi-
cacy. Even though this is probably true in the manage-
ment of metastatic breast cancer, it might not hold true
in the adjuvant setting. Data from the FinHER trial [31]
indicate that the drugs or type of chemotherapy deliv-
ered concurrently with trastuzumab probably matter.
More information from prospectively designed studies is
needed to shed light on this issue.
In three of the five published adjuvant trastuzumab tri-
als [14,18,27], trastuzumab was given on a weekly basis.
Even though this schedule is widely used in patients with
metastatic breast cancer [36,37], experience with its use
in the adjuvant setting is limited. Whether efficacy of 3-
weekly trastuzumab, as given in the present study, is
comparable to that of weekly in the adjuvant setting of
EBC, an issue that is assumed but not proven, is not
known. It is expected that a number of ongoing trials
using the 3-weekly schedule will increase our knowledge
on this critical issue, also associated with convenience
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Figure 2 Disease-free survival (A) and overall survival (B) in the total study population. Patients treated in Arms B (E-CMF-wD) and C
(E-CMF-wT) were combined and compared to the patients treated in Arm A (E-T-CMF). Log-rank p-values are reported.
Figure 3 Multivariate Cox regression analysis for DFS (A) and OS (B) presented by forest plots.






165 162 155 152 142 85 10 0Arms B and C
90 87 83 76 71 43 8 0Arm A
Patients at risk
0 12 24 36 48 60 72 84
Months




165 165 165 162 152 90 11 0Arms B and C
90 90 89 88 82 47 9 0Arm A
Patients at risk
0 12 24 36 48 60 72 84
Months
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Figure 4 Disease-free survival (A) and overall survival (B) in patients treated with trastuzumab. Patients treated in Arms B (E-CMF-wD) and
C (E-CMF-wT) were combined and compared to the patients treated in Arm A (E-T-CMF). Log-rank p-values are reported.
Table 5 Incidence of severe adverse events according to treatment arm (as treated)
Arm A: E-T-CMF Arm B: E-CMF-wD Arm C: E-CMF-wT
N = 326 N = 316 N = 320
Grade III Grade IV Grade V Grade III Grade IV Grade V Grade III Grade IV Grade V
N (%) N (%) N (%) N (%) N (%) N (%) N (%) N (%) N (%)
Hemoglobin 6 1.8 3 0.9 6 1.9
Leucocytes 28 8.6 11 3.4 36 11.4 5 1.6 32 10.0 7 2.2
Lymphopenia 2 0.6 4 1.3 1 0.3
Neutrophils 55 16.9 44 13.5 61 19.3 24 7.6 49 15.3 36 11.3
Platelets 1 0.3 1 0.3 1 0.3 1 0.3 3 0.9 1 0.3
Febrile neutropenia 17 5.2 2 0.6 1 0.3 12 3.8 1 0.3 1 0.3 13 4.1 4 1.3
Gastrointestinal 4 1.3 4 1.3
Metabolic/laboratory 12 3.7 7 2.2 1 0.3 16 5.0 5 1.6
Dermatology/skin1 5 1.5 9 2.8 1 0.3
Pain2 17 5.2 3 0.9 5 1.6
Pulmonary/Upper respiratory 2 0.6 2 0.6 1 0.3 1 0.3 1 0.3
Constitutional 1 0.3 1 0.3
Fatigue 4 1.2 7 2.2 9 2.8 1 0.3
Diarrhea 3 0.9 8 2.5 3 0.9
Nausea 7 2.1 6 1.9 10 3.1
Neurology3 16 4.9 4 1.3 4 1.3
Vomiting 5 1.5 5 1.6 1 0.3 4 1.3
Mucositis 6 1.8 1 0.3 17 5.4 10 3.1
Infection 7 2.1 1 0.3 15 4.7 7 2.2
Occular 2 0.6
Allergy4 8 2.5 2 0.6
Edema 1 0.3
Vascular 2 0.6 3 0.9 7 2.2 1 0.3
Cardiac 1 0.3 2 0.6 1 0.3 1 0.3
Anorexia 1 0.3
1P = 0.020 (Fisher’s test); 2P = 0.002; 3P = 0.004; 4P = 0.004.
N number of patients.
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http://www.biomedcentral.com/1471-2407/14/515The toxicity profile of chemotherapy in the present
study was similar to that reported in our previously con-
ducted randomized trials [20-22], even though the dose
of paclitaxel in the control arm was reduced by 20%. Pa-
tients randomized to Arm A developed more frequently
severe allergic reactions, pain and peripheral neuropathy,
while patients in Arm B suffered more frequently from
severe skin reactions. Despite the prophylactic use of G-
CSF, 5% of patients developed febrile neutropenia, which
was fatal in two cases. Furthermore, among 255 patients
that were treated with trastuzumab, only 189 (74%)
completed 1 year of treatment uneventfully.
The discontinuation rate of 1-year trastuzumab therapy
ranged from 25% to 31% in most adjuvant trials [13,27], re-
markably similar to the 26% recorded in our trial. It should
be noted however, that our study utilized a sequential
chemotherapy/trastuzumab design, as opposed to the two
referenced trials that utilized a concurrent chemotherapy/
trastuzumab design, in which patients received trastuzumab
immediately after the completion of the anthracycline and
upon initiation of the taxane treatment. Of note, in the
HERA trial [14] this rate was 8.5% excluding, however,
those patients who discontinued trastuzumab because of
disease relapse. The higher discontinuation rate observed in
our study might also be due to the fact that our study is, to
our knowledge, the only trial that used trastuzumab in a
dose-dense adjuvant chemotherapy design. The observed
relatively high discontinuation rate of both the chemother-
apy and trastuzumab regimens, mainly due to toxicity, con-
stitute a limitation of our study together with the small,
however non-negligible number of patients that changed
arm during treatment.Conclusions
In conclusion, the present trial continues to investigate,
whether a 5% difference exists in 3-year DFS between
the weekly taxane regimens and the control arm. DFS
rates in patients with HER2-positive tumors were similar
to those reported in the seminal adjuvant trastuzumab
trials. In a subgroup analysis of trastuzumab-treated pa-
tients only, DFS was significantly longer among patients
receiving a weekly taxane. Nevertheless, this was an un-
planned analysis and therefore, these data should merely
be considered as hypothesis generating, at present. Im-
portantly, to the best of our knowledge, this is the first
randomized trial, which clearly showed that the adminis-
tration of trastuzumab for 1 year following adjuvant
dose-dense chemotherapy is feasible and safe.Additional files
Additional file 1: Exclusion criteria, dose modification and radiation
therapy details.Additional file 2: Table S1. Treatment compliance and discontinuation
reasons. Table S2. Sites of relapse. Table S3. Incidence of adverse events
according to treatment arm (as treated). Figure S1. Disease-free survival
(A) and overall survival (B) of patients treated in Arm A (E-T-CMF), Arm B
(E-CMF-wD) and Arm C (E-CMF-wT). Log-rank p-values are reported.
Abbreviations
AC: Doxorubicin/cyclophosphamide; ANZCTR: Australian New Zealand
Clinical Trials Registry; CBC: Complete blood count; CI: Confidence interval;
CMF: Cyclophosphamide, methotrexate, fluorouracil; CT: Computed
tomography; DFS: Disease-free survival; DI: Dose-intensity; E: Epirubicin;
EBC: Early breast cancer; ECOG: Eastern Cooperative Oncology Group;
EF: Ejection fraction; ER: Estrogen receptors; FEC: Fluorouracil, epirubicin,
cyclophosphamide; FISH: Fluorescence in situ hybridization; HECOG: Hellenic
Cooperative Oncology Group; HER: Human epidermal growth factor
receptor; HR: Hazard ratio; IHC: Immunohistochemistry; ITT: Intent to treat;
LVEF: Left ventricular ejection fraction; MUGA: Multiple gated acquisition;
OS: Overall survival; PgR: Progesterone receptors; RT: Radiation therapy;
T: Paclitaxel; vs.: Versus; wD: Weekly docetaxel; wT: Weekly paclitaxel.
Competing interests
The senior investigator (GF) has received Commercial Research Funding by
Roche Hellas SA and Genesis Pharma SA, Athens, Greece. The rest of the
authors declare that they have no competing interests.
Authors’ contributions
GF conceived of the study, participated in its design and coordination,
contributed to the acquisition, analysis and interpretation of data and
drafted the manuscript. UD conceived of the study, participated in its design,
contributed to the analysis and interpretation of data and drafted the
manuscript. CP conceived of the study, participated in its design, contributed
to the acquisition of data and helped to draft the manuscript. ET contributed
to the acquisition of data and helped to draft the manuscript. HG conceived
of the study, participated in its design, contributed to the acquisition of data
and helped to draft the manuscript. AGE participated in the analysis and
interpretation of data and drafted the manuscript. IX contributed to the
acquisition of data. CC conceived of the study, participated in its design and
contributed to the acquisition, analysis and interpretation of data. AK
conceived of the study, participated in its design and contributed to the
acquisition, analysis and interpretation of data. CNP contributed to the
acquisition of data. PP contributed to the acquisition of data. SM contributed
to the acquisition of data. CM contributed to the acquisition of data. CD
contributed to the acquisition of data. PK contributed to the interpretation
of data. CK contributed to the acquisition of data. DB conceived of the
study, participated in its design and contributed to the acquisition of data.
PK conceived of the study, participated in its design and contributed to the
acquisition of data. ES conceived of the study, participated in its design and
contributed to the acquisition of data. IV contributed to the acquisition of
data. NP conceived of the study, participated in its design, contributed to
the acquisition of data and helped to draft the manuscript. DP conceived of
the study, participated in its design, contributed to the acquisition, analysis
and interpretation of data and helped to draft the manuscript. MAD
conceived of the study, participated in its design, contributed to the
acquisition, analysis and interpretation of data and drafted the manuscript.
All authors read and approved the final manuscript.
Acknowledgements
The authors wish to thank Evita Fragou and Dimitra Katsala for monitoring
the study, Maria Moschoni for coordinating the data management, Thalia
Spinari for tissue sample collection and Stella Dallidou for secretarial
assistance. The authors are also grateful to all patients for participating in the
trial and generously donating biological material for research purposes.
Translational research was supported by a HeCOG research grant: HE
TRANS_BR.
This work was presented in part at the European Society of Medical
Oncology (ESMO) Congress, September 2012, Vienna, Austria.
Author details
1Department of Medical Oncology, “Papageorgiou” Hospital, Aristotle
University of Thessaloniki School of Medicine, Thessaloniki Ring Road, 564 03
Fountzilas et al. BMC Cancer 2014, 14:515 Page 13 of 14
http://www.biomedcentral.com/1471-2407/14/515Thessaloniki, Macedonia, Greece. 2Laboratory of Biostatistics, University of
Athens School of Nursing, Athens, Greece. 3Department of Clinical
Therapeutics, “Alexandra” Hospital, University of Athens School of Medicine,
Athens, Greece. 4First Department of Medicine, “Laiko” General Hospital,
University of Athens, Medical School, Athens, Greece. 5Section of Biostatistics,
Hellenic Cooperative Oncology Group, Data Office, Athens, Greece. 6Second
Department of Medical Oncology, “Metropolitan” Hospital, Piraeus, Greece.
7Division of Oncology, Department of Medicine, University Hospital,
University of Patras Medical School, Patras, Greece. 8Department of Medical
Oncology, University Hospital of Larissa, University of Thessaly School of
Medicine, Larissa, Greece. 9Department of Medical Oncology, “Hippokration”
Hospital, Athens, Greece. 10First Department of Surgery, “Papageorgiou”
Hospital, Aristotle University of Thessaloniki School of Medicine, Thessaloniki,
Greece. 11Department of Obstetrics and Gynecology “Alexandra” Hospital,
Athens, Greece. 12Department of Cardiology, University of Ioannina Medical
School, Ioannina, Greece. 13Department of Medical Oncology, 424 Army
General Hospital, Thessaloniki, Greece. 14First Department of Medical
Oncology, “Metropolitan” Hospital, Piraeus, Greece. 15Second Department of
Medical Oncology, “Hygeia” Hospital, Athens, Greece. 16Third Department of
Medical Oncology, “Agii Anargiri” Cancer Hospital, Athens, Greece.
17Oncology Department, General Hospital of Chania, Crete, Greece.
18Department of Medical Oncology, Ioannina University Hospital, Ioannina,
Greece. 19Oncology Section, Second Department of Internal Medicine,
“Hippokration” Hospital, Athens, Greece.
Received: 2 July 2013 Accepted: 4 July 2014
Published: 15 July 2014
References
1. Jemal A, Siegel R, Xu J, Ward E: Cancer statistics, 2010. CA Cancer J Clin
2010, 60(5):277–300.
2. EBCTC: Effects of chemotherapy and hormonal therapy for early breast
cancer on recurrence and 15-year survival: an overview of the randomised
trials. Lancet 2005, 365(9472):1687–1717.
3. Norton L: Theoretical concepts and the emerging role of taxanes in
adjuvant therapy. Oncologist 2001, 3:30–35.
4. Lemos Duarte I, Da Silveira Nogueira Lima JP, Passos Lima CS, Deeke Sasse A:
Dose-dense chemotherapy versus conventional chemotherapy for early
breast cancer: a systematic review with meta-analysis. Breast 2012,
21(3):343–349.
5. Shao N, Wang S, Yao C, Xu X, Zhang Y, Lin Y: Sequential versus concurrent
anthracyclines and taxanes as adjuvant chemotherapy of early breast
cancer: a meta-analysis of phase III randomized control trials. Breast 2012,
21(3):389–393.
6. Peto R, Davies C, Godwin J, Gray R, Pan HC, Clarke M, Cutter D, Darby S,
McGale P, Taylor C, Wang YC, Bergh J, Di Leo A, Albain K, Swain S, Piccart
M, Pritchard K: Comparisons between different polychemotherapy
regimens for early breast cancer: meta-analyses of long-term outcome
among 100,000 women in 123 randomised trials. Lancet 2012,
379(9814):432–444.
7. Eniu A, Palmieri FM, Perez EA: Weekly administration of docetaxel and
paclitaxel in metastatic or advanced breast cancer. Oncologist 2005,
10(9):665–685.
8. Nuzzo F, Morabito A, De Maio E, Di Rella F, Gravina A, Labonia V, Landi G,
Pacilio C, Piccirillo MC, Rossi E, D’Aiuto G, Thomas R, Gori S, Colozza M,
De Placido S, Lauria R, Signoriello G, Gallo C, Perrone F, de Matteis A:
Weekly docetaxel versus CMF as adjuvant chemotherapy for elderly
breast cancer patients: safety data from the multicentre phase 3
randomised ELDA trial. Crit Rev Oncol Hematol 2008, 66(2):171–180.
9. Martin M, Pienkowski T, Mackey J, Pawlicki M, Guastalla JP, Weaver C, Tomiak E,
Al-Tweigeri T, Chap L, Juhos E, Guevin R, Howell A, Fornander T, Hainsworth J,
Coleman R, Vinholes J, Modiano M, Pinter T, Tang SC, Colwell B, Prady C,
Provencher L, Walde D, Rodriguez-Lescure A, Hugh J, Loret C, Rupin M, Blitz S,
Jacobs P, Murawsky M, Riva A, Vogel A, Breast Cancer International Research
Group 001 Investigators: Adjuvant docetaxel for node-positive breast cancer.
N Engl J Med 2005, 352(22):2302–2313.
10. Martin M, Rodriguez-Lescure A, Ruiz A, Alba E, Calvo L, Ruiz-Borrego M,
Munarriz B, Rodriguez CA, Crespo C, De Alava E, López García-Asenjo JA,
Guitián MD, Almenar S, González-Palacios JF, Vera F, Palacios J, Ramos M,
Gracia Marco JM, Lluch A, Alvarez I, Seguí MA, Mayordomo JI, Antón A,
Baena JM, Plazaola A, Modolell A, Pelegrí A, Mel JR, Aranda E, Adrover E,Alvarez JV, García Puche JL, Sánchez-Rovira P, Gonzalez S, López-Vega JM:
Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide
alone or followed by Paclitaxel for early breast cancer. J Natl Cancer Inst
2008, 100(11):805–814.
11. Sparano JA, Wang M, Martino S, Jones V, Perez EA, Saphner T, Wolff AC,
Sledge GW Jr, Wood WC, Davidson NE: Weekly paclitaxel in the adjuvant
treatment of breast cancer. N Engl J Med 2008, 358(16):1663–1671.
12. Loesch D, Greco FA, Senzer NN, Burris HA, Hainsworth JD, Jones S, Vukelja
SJ, Sandbach J, Holmes F, Sedlacek S, Pippen J, Lindquist D, McIntyre K,
Blum JL, Modiano MR, Boehm KA, Zhan F, Asmar L, Robert N: Phase III
multicenter trial of doxorubicin plus cyclophosphamide followed by
paclitaxel compared with doxorubicin plus paclitaxel followed by weekly
paclitaxel as adjuvant therapy for women with high-risk breast cancer.
J Clin Oncol 2010, 28(18):2958–2965.
13. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr, Davidson NE,
Tan-Chiu E, Martino S, Paik S, Kaufman PA, Swain SM, Pisansky TM, Fehrenbacher
L, Kutteh LA, Vogel VG, Visscher DW, Yothers G, Jenkins RB, Brown AM, Dakhil SR,
Mamounas EP, Lingle WL, Klein PM, Ingle JN, Wolmark N: Trastuzumab plus
adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J
Med 2005, 353(16):1673–1684.
14. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M,
Smith I, Gianni L, Baselga J, Bell R, Jackisch C, Cameron D, Dowsett M,
Barrios CH, Steger G, Huang CS, Andersson M, Inbar M, Lichinitser M, Láng I,
Nitz U, Iwata H, Thomssen C, Lohrisch C, Suter TM, Rüschoff J, Suto T,
Greatorex V, Ward C, Straehle C, et al: Trastuzumab after adjuvant
chemotherapy in HER2-positive breast cancer. N Engl J Med 2005,
353(16):1659–1672.
15. Joensuu H, Kellokumpu-Lehtinen PL, Bono P, Alanko T, Kataja V, Asola R,
Utriainen T, Kokko R, Hemminki A, Tarkkanen M, Turpeenniemi-Hujanen T, Jyrk-
kiö S, Flander M, Helle L, Ingalsuo S, Johansson K, Jääskeläinen AS, Pajunen M,
Rauhala M, Kaleva-Kerola J, Salminen T, Leinonen M, Elomaa I, Isola J, FinHer
Study Investigators: Adjuvant docetaxel or vinorelbine with or without
trastuzumab for breast cancer. N Engl J Med 2006, 354(8):809–820.
16. Arteaga CL, Sliwkowski MX, Osborne CK, Perez EA, Puglisi F, Gianni L:
Treatment of HER2-positive breast cancer: current status and future
perspectives. Nat Rev Clin Oncol 2011, 9(1):16–32.
17. Jelovac D, Wolff AC: The adjuvant treatment of HER2-positive breast cancer.
Curr Treat Options Oncol 2012, 13(2):230–239.
18. Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Press M, Mackey J,
Glaspy J, Chan A, Pawlicki M, Pinter T, Valero V, Liu MC, Sauter G, von Minckwitz
G, Visco F, Bee V, Buyse M, Bendahmane B, Tabah-Fisch I, Lindsay MA, Riva A,
Crown J, Breast Cancer International Research Group: Adjuvant trastuzumab in
HER2-positive breast cancer. N Engl J Med 2011, 365(14):1273–1283.
19. Gianni L, Eiermann W, Semiglazov V, Manikhas A, Lluch A, Tjulandin S,
Zambetti M, Vazquez F, Byakhow M, Lichinitser M, Climent MA, Ciruelos E,
Ojeda B, Mansutti M, Bozhok A, Baronio R, Feyereislova A, Barton C,
Valagussa P, Baselga J: Neoadjuvant chemotherapy with trastuzumab
followed by adjuvant trastuzumab versus neoadjuvant chemotherapy
alone, in patients with HER2-positive locally advanced breast cancer (the
NOAH trial): a randomised controlled superiority trial with a parallel
HER2-negative cohort. Lancet 2010, 375(9712):377–384.
20. Fountzilas G, Skarlos D, Dafni U, Gogas H, Briasoulis E, Pectasides D,
Papadimitriou C, Markopoulos C, Polychronis A, Kalofonos HP, Siafaka V,
Kosmidis P, Timotheadou E, Tsavdaridis D, Bafaloukos D, Papakostas P,
Razis E, Makrantonakis P, Aravantinos G, Christodoulou C, Dimopoulos AM:
Postoperative dose-dense sequential chemotherapy with epirubicin,
followed by CMF with or without paclitaxel, in patients with high-risk
operable breast cancer: a randomized phase III study conducted by the
Hellenic Cooperative Oncology Group. Ann Oncol 2005, 16(11):1762–1771.
21. Fountzilas G, Dafni U, Gogas H, Linardou H, Kalofonos HP, Briasoulis E,
Pectasides D, Samantas E, Bafaloukos D, Stathopoulos GP, Karina M,
Papadimitriou C, Skarlos D, Pisanidis N, Papakostas P, Markopoulos C,
Tzorakoeleftherakis E, Dimitrakakis K, Makrantonakis P, Xiros N, Polichronis A,
Varthalitis I, Karanikiotis C, Dimopoulos AM, Hellenic Cooperative Oncology
Group: Postoperative dose-dense sequential chemotherapy with epirubicin,
paclitaxel and CMF in patients with high-risk breast cancer: safety analysis
of the Hellenic Cooperative Oncology Group randomized phase III trial HE
10/00. Ann Oncol 2008, 19(5):853–860.
22. Gogas H, Dafni U, Karina M, Papadimitriou C, Batistatou A, Bobos M,
Kalofonos HP, Eleftheraki AG, Timotheadou E, Bafaloukos D, Christodoulou C,
Markopoulos C, Briasoulis E, Papakostas P, Samantas E, Kosmidis P,
Fountzilas et al. BMC Cancer 2014, 14:515 Page 14 of 14
http://www.biomedcentral.com/1471-2407/14/515Stathopoulos GP, Karanikiotis C, Pectasides D, Dimopoulos MA, Fountzilas G:
Postoperative dose-dense sequential versus concomitant administration of
epirubicin and paclitaxel in patients with node-positive breast cancer: 5-
year results of the Hellenic Cooperative Oncology Group HE 10/00 phase III
Trial. Breast Cancer Res Treat 2012, 132(2):609–619.
23. Fountzilas G, Pectasides D, Christodoulou C, Timotheadou E,
Economopoulos T, Papakostas P, Papadimitriou C, Gogas H, Efstratiou I,
Skarlos D: Adjuvant dose-dense sequential chemotherapy with epirubicin,
CMF, and weekly docetaxel is feasible and safe in patients with operable
breast cancer. Med Oncol 2006, 23(4):479–488.
24. Papadimitriou CA, Papakostas P, Timotheadou E, Aravantinos G, Bamias A,
Fountzilas G: Adjuvant dose-dense sequential chemotherapy with
epirubicin, CMF and weekly paclitaxel in patients with resected high-risk
breast cancer: a Hellenic Cooperative Oncology Group (HeCOG) study.
Cancer Invest 2008, 26(5):491–498.
25. Goldhirsch A, Glick JH, Gelber RD, Coates AS, Thurlimann B, Senn HJ:
Meeting highlights: international expert consensus on the primary
therapy of early breast cancer 2005. Ann Oncol 2005, 16(10):1569–1583.
26. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ,
Dowsett M, Fitzgibbons PL, Hanna WM, Langer A, McShane LM, Paik S,
Pegram MD, Perez EA, Press MF, Rhodes A, Sturgeon C, Taube SE, Tubbs R,
Vance GH, van de Vijver M, Wheeler TM, Hayes DF, American Society of
Clinical Oncology, College of American Pathologists: American Society of
Clinical Oncology/College of American Pathologists guideline
recommendations for human epidermal growth factor receptor 2 testing
in breast cancer. J Clin Oncol 2007, 25(1):118–145.
27. Spielmann M, Roche H, Delozier T, Canon JL, Romieu G, Bourgeois H, Extra
JM, Serin D, Kerbrat P, Machiels JP, Lortholary A, Orfeuvre H, Campone M,
Hardy-Bessard AC, Coudert B, Maerevoet M, Piot G, Kramar A, Martin AL,
Penault-Llorca F: Trastuzumab for patients with axillary-node-positive
breast cancer: results of the FNCLCC-PACS 04 trial. J Clin Oncol 2009,
27(36):6129–6134.
28. Smith I, Procter M, Gelber RD, Guillaume S, Feyereislova A, Dowsett M,
Goldhirsch A, Untch M, Mariani G, Baselga J, Kaufmann M, Cameron D, Bell
R, Bergh J, Coleman R, Wardley A, Harbeck N, Lopez RI, Mallmann P,
Gelmon K, Wilcken N, Wist E, Sánchez Rovira P, Piccart-Gebhart MJ, HERA
study team: 2-year follow-up of trastuzumab after adjuvant chemotherapy
in HER2-positive breast cancer: a randomised controlled trial. Lancet 2007,
369(9555):29–36.
29. Gianni L, Dafni U, Gelber RD, Azambuja E, Muehlbauer S, Goldhirsch A,
Untch M, Smith I, Baselga J, Jackisch C, Cameron D, Mano M, Pedrini JL,
Veronesi A, Mendiola C, Pluzanska A, Semiglazov V, Vrdoljak E, Eckart MJ,
Shen Z, Skiadopoulos G, Procter M, Pritchard KI, Piccart-Gebhart MJ, Bell R,
Herceptin Adjuvant (HERA) Trial Study Team: Treatment with trastuzumab
for 1 year after adjuvant chemotherapy in patients with HER2-positive
early breast cancer: a 4-year follow-up of a randomised controlled trial.
Lancet Oncol 2011, 12(3):236–244.
30. Perez EA, Romond EH, Suman VJ, Jeong JH, Davidson NE, Geyer CE Jr,
Martino S, Mamounas EP, Kaufman PA, Wolmark N: Four-year follow-up of
trastuzumab plus adjuvant chemotherapy for operable human epidermal
growth factor receptor 2-positive breast cancer: joint analysis of data from
NCCTG N9831 and NSABP B-31. J Clin Oncol 2011, 29(25):3366–3373.
31. Joensuu H, Bono P, Kataja V, Alanko T, Kokko R, Asola R, Utriainen T,
Turpeenniemi-Hujanen T, Jyrkkio S, Moykkynen K, Möykkynen K, Helle L,
Ingalsuo S, Pajunen M, Huusko M, Salminen T, Auvinen P, Leinonen H,
Leinonen M, Isola J, Kellokumpu-Lehtinen PL: Fluorouracil, epirubicin, and
cyclophosphamide with either docetaxel or vinorelbine, with or without
trastuzumab, as adjuvant treatments of breast cancer: final results of the
FinHer Trial. J Clin Oncol 2009, 27(34):5685–5692.
32. Pivot X, Romieu G, Debled M, Pierga JY, Kerbrat P, Bachelot T, Lortholary A,
Espié M, Fumoleau P, Serin D, Jacquin JP, Jouannaud C, Rios M, Abadie-
Lacourtoisie S, Tubiana-Mathieu N, Cany L, Catala S, Khayat D, Pauporté I,
Kramar A, PHARE trial investigators: 6 months verus 12 months of adjuvant
trastuzumab for patients with HER2-positive early breast cancer (PAHRE):
a randomized phase 3 trial. 6 months versus 12 months of adjuvant
trastuzumab for patients with HER2-positive early breast cancer (PHARE):
a randomised phase 3 trial. Lancet Oncol 2013, 14(8):741–748.
33. Goldhirsch A, Gelber RD, Piccart-Gebhart MJ, de Azambuja E, Procter M, Suter
TM, Jackisch C, Cameron D, Weber HA, Heinzmann D, Dal Lago L, McFadden E,
Dowsett M, Untch M, Gianni L, Bell R, Köhne CH, Vindevoghel A, Andersson M,
Brunt AM, Otero-Reyes D, Song S, Smith I, Leyland-Jones B, Baselga J, HerceptinAdjuvant (HERA) Trial Study Team: 2 years versus 1 year of adjuvant
trastuzumab for HER2-positive breast cancer (HERA): an open-label,
randomized controlled trial. Lancet 2013, 382(9897):1021–1028.
34. Perez EA, Suman VJ, Davidson NE, Gralow JR, Kaufman PA, Visscher DW,
Chen B, Ingle JN, Dakhil SR, Zujewski J, Moreno-Aspitia A, Pisansky TM,
Jenkins RB: Sequential versus concurrent trastuzumab in adjuvant
chemotherapy for breast cancer. J Clin Oncol 2011, 29(34):4491–4497.
35. Yin W, Jiang Y, Shen Z, Shao Z, Lu J: Trastuzumab in the adjuvant
treatment of HER2-positive early breast cancer patients: a meta-analysis
of published randomized controlled trials. PLoS One 2011, 6(6):9.
36. Seidman AD, Berry D, Cirrincione C, Harris L, Muss H, Marcom PK, Gipson G,
Burstein H, Lake D, Shapiro CL, Ungaro P, Norton L, Winer E, Hudis C:
Randomized phase III trial of weekly compared with every-3-weeks
paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2
overexpressors and random assignment to trastuzumab or not in HER-2
nonoverexpressors: final results of Cancer and Leukemia Group B
protocol 9840. J Clin Oncol 2008, 26(10):1642–1649.
37. Fountzilas G, Dafni U, Dimopoulos MA, Koutras A, Skarlos D, Papakostas P,
Gogas H, Bafaloukos D, Kalogera-Fountzila A, Samantas E, Briasoulis E,
Pectasides D, Maniadakis N, Matsiakou F, Aravantinos G, Papadimitriou C,
Karina M, Christodoulou C, Kosmidis P, Kalofonos HP: A randomized phase
III study comparing three anthracycline-free taxane-based regimens, as first
line chemotherapy, in metastatic breast cancer: a Hellenic Cooperative
Oncology Group study. Breast Cancer Res Treat 2009, 115(1):87–99.
doi:10.1186/1471-2407-14-515
Cite this article as: Fountzilas et al.: Dose-dense sequential adjuvant
chemotherapy followed, as indicated, by trastuzumab for one year in
patients with early breast cancer: first report at 5-year median follow-up
of a Hellenic Cooperative Oncology Group randomized phase III trial.
BMC Cancer 2014 14:515.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
